The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a variety of cancers, including multiple myeloma (MM). 16 Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Scottsdale, AZ.15 Division of Medical Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada and.14 Division of Hematology, Department of Medicine, and.13 Oncolytics Biotech, Calgary, AB, Canada.12 Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.11 Clinical Section of Clinical Biochemistry, Alberta Public Laboratories, Calgary, AB, Canada.10 Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.9 Histocompatibility and Immunogenetics Laboratory, Department of Pathology and Laboratory Medicine, Alberta Public Laboratories, Calgary, AB, Canada.8 Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.6 Department of Mathematics and Statistics.
5 Cancer Control, Department of Cancer Epidemiology and Prevention Research, Alberta Health Services.4 Flow Cytometry Laboratory, Department of Pathology and Laboratory Medicine, Alberta Public Laboratories, Calgary, AB, Canada.
0 kommentar(er)
